跳至主要内容
临床试验/NCT00951756
NCT00951756已完成不适用

Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Controlled Feeding Experiment of High and Low Fat Diet and Stool Microbiome Composition

James Lewis2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2009年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
10
试验地点
2
主要终点
This is not an efficacy study. There is no pre-specified clinical endpoint for this study. Rather, the outcome is the composition of the gut microbiome.

研究概览

简要总结

The purpose of this study is to determine the effect of dietary fat, in standard formulation, on the composition of the human microbiome in a prospective study of normal volunteers. Participants will be randomly assigned to either a high fat or low fat diet for 10 days. The gut microbiome will be phylotyped in fecal samples as well as in bacteria adherent to the colonic mucosa prior to, and during the course of the dietary interventions.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Basic Science
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 40 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Participant is capable of giving informed consent
  • Participant is age 18 to 40 years

排除标准

  • Diagnosis with Inflammatory bowel disease (IBD), celiac disease, or other chronic intestinal disorders.
  • Baseline bowel frequency less than every 2 days or greater than 3 times daily.
  • Current smoker.
  • Body Mass Index (BMI) <18.5 of >
  • Diabetes mellitus (DM)
  • Diagnosis with coronary artery disease, congestive heart failure, or prior myocardial infarction.
  • History of dyslipidemia or receiving treatment for hypercholesterolemia. This will be defined as a fasting LDL >160 mg/dL or a non-fasting total cholesterol >200 mg/dL or non-fasting HDL<40 mg/dl. Additionally, patients receiving drug therapy for hypercholesterolemia will be excluded.
  • Prior bowel resection surgery.
  • Contraindication to flexible sigmoidoscopy and biopsies. Patients with suppressed white blood count may be at increased risk of systemic infection following sigmoidoscopy with biopsies. As such, subjects with a white blood cell (WBC) count less than 3,500 or an absolute neutrophil count of less than 1,000 will be excluded. Patients with thrombocytopenia or with a coagulopathy may be at increased risk of bleeding complications after colonoscopic biopsies. As such, patients with a platelet count of less than 100,000 or an international normalized ratio (INR) greater than 1.2 will be excluded from the study.
  • Student or employee of any one of the investigators.
  • Pregnant women.
  • Use of antibiotics in the prior 6 months.
  • Use of antacids, non-steroidal anti-inflammatory drugs (NSAIDs), or dietary supplements in the preceding 2 weeks.
  • Use of any of the following medications in the 4 weeks prior to randomization: proton pump inhibitors (PPI), histamine receptor antagonists, narcotics, tricyclic antidepressants, anticholinergics (e.g., hyoscamine), metoclopramide, anti-diarrhea medications, laxatives.
  • HIV infection, AIDS, or other known conditions resulting in immunosuppression.
  • Allergies or intolerance to the components of the study diets.
  • Participant has experienced diarrhea within the two weeks prior to the first sigmoidoscopy. Diarrhea is defined as a change in bowel habits with an increased frequency or loose stools such that the stool could not be lifted with a fork.
  • Any condition that the investigator feels may limit the volunteer's ability to complete the study protocol.

结局指标

主要结局

This is not an efficacy study. There is no pre-specified clinical endpoint for this study. Rather, the outcome is the composition of the gut microbiome.

时间窗: 10 days

次要结局

未报告次要终点

研究者

发起方
James Lewis
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

James Lewis

Professor of Medicine and Epidemiology

University of Pennsylvania

研究点 (2)

Loading locations...

相似试验

Controlled Feeding Experiment | 临床试验